Pune, India, October 2022/MRFR Press Release/- Market Research Future has published a half-cooked research report on the global apoptosis assays market.
The global apoptosis assays market is projected to hit USD 2.99 billion by 2030 and is expected to register a CAGR of 9.80% during the forecast period (2022-2030).
Increasing R&D expenses and growing cell-based research are expected to drive the growth of the market. On the other hand, required high investment for research activities can restrain the market growth over the assessment period. Recently, in 2016, the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and the Stein Eye Institute received USD 5.1 million from the California Institute for Regenerative Medicine. This funding helps for the development of novel therapy for blinding retinal conditions. Furthermore, the National Institutes of Health (NIH) invested USD 1.65 billion for stem cell research in 2017. This funding drives the growth of the apoptosis assays market.
Geographically, the Americas is expected to dominate the global market owing to the presence of well-established players and increasing funding for cell-based research. Europe is expected to hold the second largest position in the global market. Asia-Pacific is expected to be the fastest growing market. Furthermore, the Middle Eastern and African region is expected to account for the least market share in the global market.
The global apoptosis assays market has been segmented into product, detection technology, application, and end user.
Based on product, the market is segmented into kits, reagents, instruments, and others. The kits segment accounted for the largest share and fastest growing segment of the global apoptosis assays market in 2017.
Based on detection technology, the market is segmented into flow cytometry, fluorescence microscopy, western blot assessment, gel electrophoresis, and others. The flow cytometry segment accounted for the largest share segment of the global apoptosis assays market in 2017.
Based on application, the market has been segmented into drug discovery and development, stem cell research, and others. The drug discovery and development segment accounted for the largest share of the global apoptosis assays market in 2017. The stem cell research was the fastest growing segment of the global apoptosis assays market in 2017.
Based on end user, the market has been segmented into pharmaceutical and biological companies, research institutes, and others. The pharmaceutical and biological companies segment accounted for the largest share of the global apoptosis assays market in 2017. Research institutes were the fastest growing segment of the global apoptosis assays market in 2017.
Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Apoptosis Assays Market Research Report
Some of the prominent players in the global apoptosis assays market are Abcom plc (US), Merck KGaA (Germany), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), GE Healthcare (US), Danaher Corporation (US), Becton, Dickinson and Company (US), Sartorius AG (Germany), Geno Technology (US), GeneCopoeia, Inc. (US), and Promega Corporation (US).
Some of the key players in the global Apoptosis Assays market are WuXi AppTec, Charles River, SGS SA, Merck KGaA, NORTH AMERICAN SCIENCE ASSOCIATES INC., Becton, Dickinson, and Company, Nelson Laboratories, LLC, Pacific Biolabs, ATS Laboratories, Inc., and Dynatec Labs.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
+1 646 845 9312
Email: email@example.com .